Hard charg­ing Neu­ro­crine hit with a sud­den set­back as Tourette study flops

Kevin Gor­man, CEO of Neu­ro­crine Bio­sciences, presents at a Jef­feries in­vestor con­fer­ence in 2013. bloomberg/via get­ty im­ages

Neu­ro­crine has been on a roll for the past five weeks — right up to Tues­day evening.

First the FDA ap­proved In­grez­za (val­be­nazine) for tar­dive dysk­i­ne­sia in April, their first ever reg­u­la­to­ry OK. Then just a few days ago its part­ner Ab­b­Vie came through with promis­ing late-stage da­ta for their en­dometrio­sis drug elagolix, out­li­censed to them in 2010.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.